Alliqua Biomedical (ALQA) Getting Somewhat Favorable Media Coverage, Study Finds

Press coverage about Alliqua Biomedical (NASDAQ:ALQA) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alliqua Biomedical earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.4174035583531 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Alliqua Biomedical from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Alliqua Biomedical in a research note on Monday, September 18th. Finally, ValuEngine raised shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a research note on Friday, October 6th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.25.

Alliqua Biomedical (NASDAQ ALQA) opened at $2.11 on Wednesday. Alliqua Biomedical has a 12 month low of $1.99 and a 12 month high of $8.50.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at

About Alliqua Biomedical

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Insider Buying and Selling by Quarter for Alliqua Biomedical (NASDAQ:ALQA)

Receive News & Ratings for Alliqua Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical Inc and related companies with's FREE daily email newsletter.

Leave a Reply